skip to Main Content

We are developing

Tomorrow’s immuno – modulators oncology therapy
A single platform for defeating cancer and much more.

A single platform for defeating cancer

We are HEPHAISTOS-Pharma

A preclinical stage Biotech company developing the next generation of oncology treatments that will boost the immune system to treat incurable cancers.

One need, one mission :

Immunotherapies have shown impressive results in the past years, by treating cancers like never before. Unfortunately, success level are still very low and only 10% of patients can be cured today.

Our mission is to take Immunotherapy to the next level of efficiency by stimulating patients’ immune response and turning hidden “cold” tumors into “hot” targets for our immune system.

Scientific Founders

team-1

Dr. Martine CAROFF, Chief Scientific Officer

DSc., Former Academic Research director, TLR4 agonist biochemistry expert. Founder and inventor of the technology. EU Woman Innovators Prize 2019.

team-6

Pr. Charles Dumontet,
Deputy Director CRCL Physician in Hematology. Oncology KOL.

Pr. of Hematology in University of Lyon Deputy Director CRCL. President of the Clinical Research and Innovation Department and also Vice-President of Research at HCL

Team

team-3

Frederic CAROFF

CEO
MSc Centrale Paris, MBA Essec, 12 years experience as Biotech CEO,

Jerome-Kerzerho-NB-190x190 (1)

Jérôme KERZERHO

Preclinical Development Manager
PhD, Drug development, Immuno-therapy expert.

Simon PIco 2 NB

Simon PICO

Business Developer
MSc, EMBA EMLyon, Biotech Ecosystem expert, Business Angel

Christel Lonneux

Christel LONNEUX

CFO and HR
Finance auditing, Biotech financing

team-4

Alexey NOVIKOV

CMC Manager
PhD, Head of Research Ability. Chemistry and Mass Spectrometry expert.

Christophe-Anciaux

Christophe ANSIAUX

GMP Transfer Manager
PhD, CDMO and BIOTECH GMP manufacturing

Board Members

David Sourdive portrait

David SOURDIVE

Chairman
Founder and executive VP at CELLECTIS, Former Chairman at MABLINK

Florian Denis portrait

Florian DENIS

Board member
Investment Director at ELAIA

Ingrid Kelly portrait

Ingrid KELLY

Board member
Partner at xista Science Ventures

Jerome-Majoie_1375x1375px-300x300

Jerome MAJOIE

Board member
CEO and Founder at fondation FOURNIER-MAJOIE

Frederic Schynts copie

Frederic SCHYNTS

Board member
Investment Manager at NOSHAQ

Scientific Advisory Board

jean-yves-blay NB

Pr. Jean-Yves Blay, MD PhD

General Director at the Centre Léon Bérard, Oncology KOL.

President of the French Federation of Cancer Centers Unicancer, coordinator of European Reference Network on rare adult cancers, EURACAN

eric chetaille

Dr. Eric Chetaille, MD

Oncology Clinical Consultant

Former Head of Oncology Innovation Unit at Pierre Fabre, VP Oncology Development at Ipsen.

Frédérique Brune NB

Dr. Frederique Brune, PharmD

Managing Director, Head of R&D at Mablink

Biotech drug development. Strong pharmaceutical background as Responsible Pharmacist. Trained in experimental and clinical pharmacology.

Peter-De-Waele-square-bw

Dr. Peter de Waele, PhD

Consultant Immunotherapy

Expert in immunotherapies for the Fondation FOURNIER-MAJOIE, former VP R&D and IP at CELYAD

team-5

Dr. Nathalie Garçon, PharmD PhD

Consultant, Adjuvant KOL

Former CEO at BIOASTER, Former Vice President, Head of the Adjuvant and Technology Innovation Center at GSK Vaccines, 2014 Stanley Plotkin Award for lifetime achievement in vaccines

Market Needs

Turning cold tumors into hot tumors

Only 10% of current immunotherapies are successful
Need for stronger and safer immuno-modulators
to turn cold tumors into hot tumors and improve cancer therapy

Innovation & advantages

Onco-Boost platform

ONCO-Boost is the First-In-Class Immunostimulant injectable intravenously, able to treat metastatic and hardly accessible cancer like Osteorsarcoma

Mechanism of Action

Mechanism of Action (MoA)

ONCO-Boost

will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.

Monoclonal
Antibody (mAb)

will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumors as targets to destroy.

All together

By recruiting and stimulating immune cells, ONCO-Boost enables the treatment of tumors that were not previously sensitive to mAb’s action and opens the way to treat incurable cancers.

Pipeline

Immuno Oncology

ONCO-Boost Immunotherapy

Human Vaccine

VAXI-Boost natural adjuvant

News

HEPHAISTOS secures €10.3 M to reach the clinical stage

HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round,…

Read more

Frederic CAROFF will attend BIO Europe Spring in Barcelona

Our CEO, Frederic CAROFF will be attending BIO-Europe…

Read more

HEPHAISTOS-Pharma secures a €2 million seed round

HEPHAISTOS-Pharma secures a €2 million seed round with…

Read more

HEPHAISTOS Laureate of the SANOFI Golden Ticket mRNA

  🏆 We are pleased to announce that…

Read more

Clusters & Partners

Financial Supports

HEPHAISTOS-Pharma has received funding from ANR (#ANR-23-RHUS-0003) and received State support through France 2030 program.

HEPHAISTOS-Pharma has received funding from the European Union – Next Generation EU through the program France Relance.

HEPHAISTOS-Pharma has received funding from the European Union EIC Accelerator program

HEPHAISTOS-Pharma has received funding from the European Union FEDER regional fund

HEPHAISTOS-Pharma has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 868937

HEPHAISTOS-Pharma’s academic partner CRCL has received funding from the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.

HEPHAISTOS-Pharma received financial support from WILCO Healthcare startup cluster.

Contact

    *

    *

    *

    *

    Back To Top